TheryCell coordinates an innovative project to advance TCR-T therapy for solid tumors with partners Charité, HS Diagnomics GmbH, and EPO GmbH
Berlin, October 30, 2023 - TheryCell is coordinating a cutting-edge project together with partners HS Diagnomics GmbH, EPO GmbH and Charité, aimed at developing novel cellular immunotherapies (TCR-T) of solid cancers. A central component will be the identification and preclinical validation of tumor-specific T-cell receptors (TCRs) which are determined for each patient individually.
Building upon a patented antigen-agnostic approach successfully validated in Non-Small Cell Lung Cancer (NSCLC), this novel methodology to identify and employ tumor-specific T-cell receptors will now be extended to more solid cancers with high medical need.
The collaborative effort of three Biotech companies and the Dept. of Hematology, Oncology & Cancer Immunology and the Institute of Pathology of the Charité will focus on identifying and validating tumor-specific T-cell receptors for Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Carcinoma (CRC), and Breast Cancer (BC). This ambitious project aims to advance TCR-T therapies ranging from the selection of therapeutic TCRs to establishing a GMP-compliant workflow for the manufacture of therapeutic doses of personalized as well as off-the-shelf TCR-T cell therapies.
The project is funded for three years by the ProFIT program of the IBB Berlin and the European Union (EFRE, Europäischer Fonds für regionale Entwicklung), underscoring the significance and potential impact of this pioneering initiative.
